Table 1. Description of the VersKiK cohort: 5-year survivors of childhood cancer in Germany (cancer diagnosis 1991–2011).
| Five-year survivors 1 | |
|---|---|
| Sex (N,%) | |
| Female | 5236 (44.1%) |
| Male | 6627 (55.9%) |
| Primary cancer diagnosis (N, %) | |
| Lymphoid leukemia | 3459 (29.5%) |
| Acute myeloid leukemia | 478 (4.0%) |
| Hodgkin lymphoma | 669 (5.6%) |
| Non-Hodgkin lymphoma | 825 (7.0%) |
| CNS tumor | 2413 (20.3%) |
| Neuroblastoma | 789 (6.7%) |
| Renal tumor | 758 (6.4%) |
| Bone tumor | 466 (4.0%) |
| Soft tissue sarcoma | 618 (5.2%) |
| Intracranial germ cell tumor | 120 (1.0%) |
| Other diagnoses | 1268 (10.7%) |
| Vital status at 31 December 2021 | |
| Alive | 11 681 (98.5%) |
| Deceased 2017–2021 | 182 (1.5%) |
| Median age at 1 January 2017* (years) | 21.5 (IQR 15.5–26.5) |
| Median time from cancer diagnosis to at least January 2017 (years) | 14.5 (IQR 9.5–19.5) |
| Total | 11 863 (100%) |
*
Start date of the insurance period: monitoring of health events (1 January 2017 to 31 December 2021)
CNS, Central nervous system; IQR, interquartile range